BioCardia (BCDA) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCardia (BCDA) has outperformed Jasper Therapeutics (JSPR) over the past year, losing 25.4% versus a loss of 76.7%. Over five years, BCDA leads with a -97.6% price change compared with -99.7% for JSPR. Jasper Therapeutics is the larger company by market cap ($18.6 million vs $16.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | JSPR |
|---|---|---|
| Share price | $1.06 | $0.56 |
| Market cap | $16.05M | $18.63M |
| 1-day change | -2.75% | -1.70% |
| YTD return | -15.20% | -69.40% |
| 1-year return | -25.35% | -76.67% |
| 5-year return | -97.59% | -99.66% |
| EPS (TTM) | $-0.64 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $2.69 |
| 52-week low | $0.75 | $0.315 |
| Distance from 52-week high | -41.11% | -79.18% |
| Analyst consensus | none | none |
| Avg. price target upside | +1362.26% | +3471.43% |
| Average volume | 282.05K | 1.37M |
| Shares outstanding | 15.14M | 33.27M |
| Employees | 17 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed JSPR by 51.3 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Healthcare · Biotechnology
BCDA vs JSPR FAQ
Which is bigger, BioCardia or Jasper Therapeutics?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $18.63M compared with $16.05M for BioCardia (BCDA).
Which stock has performed better over the past year, BCDA or JSPR?
BCDA returned -25.35% over the past 12 months, compared with -76.67% for JSPR (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.